AveXis, a Novartis company, has agreed to purchase a former AstraZeneca site in Longmont, Colorado. AstraZeneca had laid off a majority of the site's employees in January, but they may now be by AveXis.
The Novartis subsidiary plans to offer positions to the 150 employees who worked at the site.
The six-building Longmont campus with about 700,000 square feet is slated to become the largest of the company's four facilities involved in the manufacturing of gene therapies for the treatment of rare diseases.
The Longmont campus, along with existing manufacturing sites in Illinois, California and North Carolina, will become the largest of four sites involved in manufacturing of AveXis gene therapies for pipeline of rare genetic diseases including spinal muscular atrophy
Read the full release.